
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx Inc. is exhibiting strong performance with a notable 19% year-over-year growth in kidney surveillance volumes in Q2 2025, indicating increased demand for its testing services. The company has strategically expanded its sales force by approximately 50%, which is expected to enhance its market penetration and revenue growth over the coming months as the new representatives ramp up. Additionally, CareDx has set a targeted EBITDA margin of 20% for 2027, along with an ambition to boost its three-year incremental cash target by over $100 million, reflecting a commitment to improving financial performance and operational efficiency.
Bears say
CareDx Inc has faced significant risks stemming from multiple changes in management over the past three years, which may undermine operational stability and strategic direction. The company's growth strategy crucially relies on the successful commercialization of additional diagnostic solutions; however, there is skepticism surrounding this capability. Furthermore, while CareDx has expressed hopes for reimbursement increases for kidney testing, there is a noted lack of confidence in achieving these expansions, adding to the uncertainty about future revenue growth.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares